O-Desmethyltramadol (O-DSMT), also known by its INN desmetramadol, is the primary active metabolite of the prescription analgesic tramadol. Unlike its parent compound — which produces analgesia through a dual mechanism combining weak mu-opioid agonism with serotonin-norepinephrine reuptake inhibition (SNRI) — O-DSMT is essentially apure mu-opioid receptor agonist with approximately 200-300 times greater binding affinity for the mu receptor than tramadol itself .
In the body, tramadol is converted to O-DSMT primarily by the hepatic enzyme CYP2D6. This conversion is clinically critical: individuals who are CYP2D6 poor metabolizers may experience little analgesic benefit from tramadol, while ultra-rapid metabolizers can produce dangerously high O-DSMT levels . The compound's potency — roughly 6 times greater than tramadol in analgesic models — combined with its pure opioid mechanism has made it a subject of both pharmaceutical research and concern in the novel psychoactive substance (NPS) market, where it has been sold as a research chemical since the mid-2010s .
O-DSMT has attracted pharmaceutical interest as a potential standalone analgesic, with clinical trials suggesting it may offer morphine-equivalent analgesia with a potentially improved safety profile due to its G-protein biased signaling at the mu receptor .
References
Gillen C et al. Affinity, potency and efficacy of tramadol and its metabolites at the cloned human mu-opioid receptor. Naunyn Schmiedebergs Arch Pharmacol. 2000;362(2):116-121. Grond S, Sablotzki A. Clinical pharmacology of tramadol. Clin Pharmacokinet. 2004;43(13):879-923. NCBI Bookshelf. Tramadol Therapy and CYP2D6 Genotype. Medical Genetics Summaries. NBK315950. PubChem. Desmetramadol. CID 9838803. Rosenthal NR et al. Desmetramadol has the safety and analgesic profile of tramadol without its metabolic liabilities. J Pain. 2019;20(10):1218-1230.
Safety at a Glance
High Risk- Fentanyl Testing
- Start Low, Go Slow
- Toxicity: Toxicity Profile O-Desmethyltramadol occupies a unique toxicological position: it is pharmacologically a pure mu-opio...
- Dangerous with: 3-Cl-PCP, 3-HO-PCE, 3-HO-PCP, 3-MeO-PCE (+43 more)
- Overdose risk: Overdose Information Recognition O-DSMT overdose presents as a classic opioid overdose syndrome c...
If someone is in crisis, call 911 or Poison Control: 1-800-222-1222
Dosage
oral
sublingual
intravenous
Duration
oral
Total: 6 hrs – 10 hrssublingual
Total: 5 hrs – 10 hrsintravenous
Total: 5 hrs – 8 hrsHow It Feels
O-Desmethyltramadol is tramadol's active metabolite stripped of its parent compound's noradrenergic and serotonergic complications, and the resulting experience is cleaner, more purely opioid in character. The onset takes thirty to sixty minutes, a patient accumulation of warmth that begins as a faint glow in the abdomen and slowly radiates outward. There is none of the buzzy, stimulating quality that tramadol often produces -- no racing thoughts, no jittery energy. Instead, the buildup is smooth and unidirectional, tilting steadily toward warmth and sedation.
As the compound reaches its working level, the body softens with a thoroughness that belies its moderate potency. Muscles loosen. The chronic background hum of minor aches and tensions fades to silence. There is a warmth here that is genuine and satisfying, more substantial than codeine but less overwhelming than morphine -- a comfortable middle ground that provides real relief without demanding total surrender. The emotional shift is toward contentment, a quiet lifting of the mood that makes ordinary moments feel slightly more pleasant, slightly more meaningful than they normally would.
The peak has a clean, focused quality. Unlike tramadol, which can produce a confusing mixture of opioid warmth and stimulant-like activation, O-desmethyltramadol delivers its effects through a single pharmacological channel. The result is a clarity within the warmth -- you feel comforted and relaxed without the scattered, unfocused quality that can accompany tramadol's polypharmacology. Drowsiness is moderate and pleasant, a soft invitation to rest rather than an irresistible pull. The itch is mild. Nausea is possible but less common than with the parent compound, and the risk of seizure -- tramadol's most feared complication -- is dramatically reduced.
The duration is moderate, with primary effects lasting four to six hours and a gentle decline that stretches the total experience to eight hours or more. The plateau is stable and predictable, maintaining a consistent level of comfort that allows for either rest or gentle activity. There is a reliability to the experience that makes it feel almost medicinal in its precision -- warmth delivered within known parameters, without surprises.
The comedown is smooth and uneventful. The warmth recedes gradually, leaving behind a mild drowsiness and a residual sense of physical ease that takes several more hours to fully dissipate. There is no significant rebound, no harsh return to baseline -- just a quiet, dignified retreat that allows ordinary consciousness to reassert itself without friction. Sleep comes easily, and the following morning carries no hangover, only a faint memory of warmth.
Subjective Effects
The effects listed below are based on the Subjective Effect Index (SEI), an open research literature based on anecdotal reports and personal analyses. They should be viewed with a healthy degree of skepticism. These effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects.
Physical Effects
Physical(21)
- Appetite suppression— A distinct decrease in hunger and desire to eat, ranging from reduced interest in food to complete d...
- Constipation— A slowing or cessation of bowel movements resulting in difficulty passing stool, commonly caused by ...
- Cough suppression— A decreased desire and need to cough, medically known as antitussive action, which can also allow in...
- Decreased libido— Decreased libido is a diminished interest in and desire for sexual activity, commonly caused by subs...
- Diarrhea— Diarrhea is the occurrence of frequent, loose, or watery bowel movements as a side effect of certain...
- Difficulty urinating— Difficulty urinating, also known as urinary retention, is the experience of being unable to easily p...
- Headache— A painful sensation of pressure, throbbing, or aching in the head that can range from a dull backgro...
- Increased heart rate— A noticeable acceleration of heartbeat that can range from a subtle awareness of one's pulse to a fo...
- Itchiness— A persistent, diffuse urge to scratch the skin that arises without any external irritant, most commo...
- Motor control loss— A distinct decrease in the ability to control one's physical body with precision, balance, and coord...
- Nausea— An uncomfortable sensation of queasiness and stomach discomfort that may or may not lead to vomiting...
- Orgasm suppression— Orgasm suppression (anorgasmia) is the difficulty or complete inability to achieve orgasm despite ad...
- Pain relief— A suppression of negative physical sensations such as aches and pains, ranging from dulled awareness...
- Physical euphoria— An intensely pleasurable bodily sensation that can manifest as waves of warmth, tingling electricity...
- Pupil constriction— A visible narrowing of the pupil diameter (miosis) that reduces the size of the dark center of the e...
- Respiratory depression— A dangerous slowing and shallowing of breathing that can progress from barely noticeable reductions ...
- Sedation— A state of deep physical and mental calming that manifests as a progressive desire to remain still, ...
- Seizure— Uncontrolled brain electrical activity causing convulsions and loss of consciousness -- a life-threa...
- Serotonin syndrome— Serotonin syndrome is a potentially fatal medical emergency caused by excessive serotonergic activit...
- Spontaneous physical movements— Spontaneous physical movements are involuntary, seemingly random yet patterned body movements — twit...
- Stimulation— A state of heightened physical and mental energy characterized by increased wakefulness, elevated mo...
Cognitive & Perceptual Effects
Cognitive(7)
- Amnesia— A complete or partial inability to form new memories or recall existing ones during and after substa...
- Anxiety— Intense feelings of apprehension, worry, and dread that can range from a subtle background unease to...
- Anxiety suppression— A partial to complete suppression of anxiety and general unease, producing a calm, relaxed mental st...
- Cognitive euphoria— A cognitive and emotional state of intense well-being, elation, happiness, and joy that manifests as...
- Compulsive redosing— An overwhelming, difficult-to-resist urge to continuously take more of a substance in order to maint...
- Depression— A persistent state of low mood, emotional numbness, hopelessness, and diminished interest or pleasur...
- Dream potentiation— Enhanced dream vividness, complexity, and recall, often occurring as REM rebound after discontinuing...
Pharmacology
Pharmacology
Receptor Binding Profile
O-Desmethyltramadol is a high-affinity mu-opioid receptor (MOR) agonist, with binding affinity (Ki) of approximately3.4 nM at the mu receptor — a dramatic contrast to tramadol's weak affinity of roughly 2,400 nM (2.4 microM) . This approximately 700-fold difference in binding affinity explains why O-DSMT is the primary mediator of tramadol's analgesic effects.
The compound also displays modest affinity for delta and kappa opioid receptors, though these interactions are substantially weaker than its mu-receptor activity and are not considered major contributors to its pharmacological profile at typical doses.
Stereochemistry
O-DSMT exists as two enantiomers with meaningfully different pharmacological profiles. (+)-O-Desmethyltramadol is the more potent enantiomer at the mu-opioid receptor and is primarily responsible for the compound's analgesic effects.(-)-O-Desmethyltramadol retains some activity as a noradrenaline reuptake inhibitor but is substantially less potent at the mu receptor . The racemic mixture is what is typically encountered both clinically (as a metabolite) and in the research chemical market.
Absence of SNRI Activity
A defining pharmacological distinction between O-DSMT and its parent tramadol is the effective loss of serotonin-norepinephrine reuptake inhibition. While tramadol's (+)-enantiomer is a serotonin reuptake inhibitor and its (-)-enantiomer inhibits norepinephrine reuptake, these monoaminergic effects are dramatically reduced in O-DSMT. Both enantiomers of O-DSMT are inactive as serotonin reuptake inhibitors, and the (-)-enantiomer retains only modest noradrenergic activity . This makes O-DSMT pharmacologically apure opioid in practical terms — it lacks the "atypical" character of tramadol.
G-Protein Biased Signaling
Research has identified O-DSMT as a G-protein biased mu-opioid receptor agonist — it potently activates G-protein signaling (the pathway associated with analgesia) while showing markedly reduced recruitment of beta-arrestin2 (the pathway associated with respiratory depression, constipation, and tolerance). This biased signaling profile may explain the clinical observation that tramadol and its metabolite carry a relatively lower risk of fatal respiratory depression compared to conventional opioids .
Onset and Duration
When encountered as a standalone compound (rather than generated in vivo from tramadol), O-DSMT has a faster onset than oral tramadol because it bypasses the CYP2D6-dependent metabolic conversion step. Oral onset is typically 15-30 minutes, with effects lasting 4-6 hours.
References
Gillen C et al. Affinity, potency and efficacy of tramadol and its metabolites at the cloned human mu-opioid receptor. Naunyn Schmiedebergs Arch Pharmacol. 2000;362(2):116-121. Raffa RB et al. Actions of tramadol, its enantiomers and principal metabolite, O-desmethyltramadol, on serotonin (5-HT) efflux and uptake in the rat dorsal raphe nucleus. Br J Anaesth. 1997;79(3):352-356. ScienceDirect. O-Desmethyltramadol. Topics in Pharmacology, Toxicology and Pharmaceutical Science. Uprety R et al. Desmetramadol is identified as a G-protein biased mu opioid receptor agonist. Front Pharmacol. 2020;10:1680.
Detection Methods
Standard Drug Panel Inclusion
O-Desmethyltramadol is a synthetic opioid that is not detected on standard 5-panel immunoassay drug screens. Tramadol and its metabolites require a tramadol-specific immunoassay channel, which is available on some expanded panels but is not part of standard 5-panel or 10-panel screens. Standard opiate immunoassays target the morphine backbone structure, and synthetic opioids lack this structural motif. Detection of O-Desmethyltramadol requires either an expanded panel with a specific immunoassay channel or confirmatory instrumental analysis.
Urine Detection
O-Desmethyltramadol and its metabolites can be detected in urine for approximately 2 to 4 days after a single dose, though this varies with dose, frequency of use, and individual metabolism. Synthetic opioids undergo extensive hepatic metabolism, primarily via cytochrome P450 enzymes, producing metabolites that are excreted renally. The metabolite profile is specific to O-Desmethyltramadol and does not overlap with morphine-class metabolites used as markers in standard opiate screens.
Blood and Saliva Detection
Blood concentrations of O-Desmethyltramadol are typically detectable for 12 to 48 hours, depending on the half-life and dose administered. Oral fluid testing can detect O-Desmethyltramadol for a similar window. Blood testing is most commonly used in emergency department settings, postmortem toxicology, and driving-under-the-influence investigations.
Hair Follicle Detection
Hair follicle testing can detect O-Desmethyltramadol for up to 90 days. However, synthetic opioids are not always included in standard hair testing panels. Specialized forensic or clinical laboratories may offer expanded panels that include O-Desmethyltramadol, but this must be specifically requested. LC-MS/MS with appropriate reference standards is required.
Confirmatory Testing
Liquid chromatography-tandem mass spectrometry (LC-MS/MS) is the definitive method for identifying O-Desmethyltramadol in biological specimens. GC-MS is also effective for many synthetic opioids. These instrumental methods provide the specificity needed to distinguish O-Desmethyltramadol from other opioids and from endogenous compounds. Quantitative analysis can determine concentrations relevant to therapeutic monitoring, compliance testing, or forensic investigation.
Reagent Testing
Reagent testing for O-Desmethyltramadol depends on its specific chemical structure. Marquis reagent may produce little or no reaction, which is itself informative as it distinguishes synthetic opioids from morphine-class opiates (which turn purple). Mecke reagent may show a faint color change. Fentanyl-specific test strips are available for harm reduction purposes but their cross-reactivity with non-fentanyl synthetic opioids varies. Mass spectrometry remains the only reliable identification method.
Interactions
| Substance | Status | Note |
|---|---|---|
| 3-Cl-PCP | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| 3-HO-PCE | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| 3-HO-PCP | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| 3-MeO-PCE | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| 3-MeO-PCMo | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| 3-MeO-PCP | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| 4-MeO-PCP | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| Alcohol | Dangerous | — |
| Atropa belladonna | Dangerous | Compounding CNS depression with anticholinergic effects; risk of cardiac events and respiratory failure |
| Benzodiazepines | Dangerous | — |
| Cake | Dangerous | Severe respiratory depression risk; leading cause of polydrug overdose |
| Datura | Dangerous | Compounding CNS depression with anticholinergic effects; risk of cardiac events and respiratory failure |
| Deschloroetizolam | Dangerous | Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths |
| Deschloroketamine | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| Desomorphine | Dangerous | Compounding respiratory depression and overdose risk |
| Diclazepam | Dangerous | Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths |
| Diphenhydramine | Dangerous | Compounding CNS depression with anticholinergic effects; risk of cardiac events and respiratory failure |
| Diphenidine | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| Ephenidine | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| Eszopiclone | Dangerous | Severe respiratory depression risk; leading cause of polydrug overdose |
| Etizolam | Dangerous | Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths |
| Flubromazepam | Dangerous | Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths |
| Flubromazolam | Dangerous | Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths |
| Flunitrazepam | Dangerous | Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths |
| Flunitrazolam | Dangerous | Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths |
| Gaboxadol | Dangerous | Severe respiratory depression risk; leading cause of polydrug overdose |
| GBL | Dangerous | — |
| GHB | Dangerous | — |
| Harmala alkaloid | Dangerous | Risk of serotonin syndrome and severe respiratory depression; potentially fatal |
| HXE | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| Inhalants | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| Ketamine | Dangerous | — |
| Lorazepam | Dangerous | Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths |
| Memantine | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| Mephenaqualone | Dangerous | Severe respiratory depression risk; leading cause of polydrug overdose |
| Metizolam | Dangerous | Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths |
| Midazolam | Dangerous | Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths |
| MXiPr | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| Naloxone | Dangerous | Compounding respiratory depression and overdose risk |
| Nicotine | Dangerous | Severe respiratory depression risk; leading cause of polydrug overdose |
| Nifoxipam | Dangerous | Severe respiratory depression risk; leading cause of polydrug overdose |
| O-PCE | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| PCE | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| Peganum harmala | Dangerous | Risk of serotonin syndrome and severe respiratory depression; potentially fatal |
| Pentobarbital | Dangerous | Severe respiratory depression risk; leading cause of polydrug overdose |
| Phenobarbital | Dangerous | Severe respiratory depression risk; leading cause of polydrug overdose |
| SAMe | Dangerous | Severe respiratory depression risk; leading cause of polydrug overdose |
| 3-FMA | Caution | Stimulants mask opioid sedation, increasing overdose risk when the stimulant wears off |
| 4-MMC | Caution | Stimulants mask opioid sedation, increasing overdose risk when the stimulant wears off |
| 8-Chlorotheophylline | Caution | Stimulants mask opioid sedation, increasing overdose risk when the stimulant wears off |
| Adrafinil | Caution | Stimulants mask opioid sedation, increasing overdose risk when the stimulant wears off |
| Benzydamine | Caution | Stimulants mask opioid sedation, increasing overdose risk when the stimulant wears off |
| Nitrous | Uncertain | — |
| PCP | Uncertain | — |
| 1,3-Butanediol | Low Risk & No Synergy | No significant pharmacological interaction; opioids may slightly dull the psychedelic experience |
| 25E-NBOH | Low Risk & No Synergy | No significant pharmacological interaction; opioids may slightly dull the psychedelic experience |
| 2C-T | Low Risk & No Synergy | No significant pharmacological interaction; opioids may slightly dull the psychedelic experience |
History
O-Desmethyltramadol belongs to the opioid class of substances, which has a history spanning thousands of years from the ancient use of opium poppy to modern synthetic and semi-synthetic analogues.
The isolation of morphine from opium in 1804 by Friedrich Sertürner marked the beginning of modern opioid pharmacology. Subsequent developments included the synthesis of heroin (diacetylmorphine) in 1874, the development of numerous semi-synthetic and fully synthetic opioids throughout the 20th century, and the identification of endogenous opioid receptors and peptides in the 1970s.
The opioid crisis of the early 21st century, driven largely by overprescription of pharmaceutical opioids and the subsequent emergence of illicit fentanyl and its analogues, represents one of the most significant public health challenges in modern history. This crisis has fundamentally reshaped discussions around opioid prescribing, addiction treatment, and harm reduction policy.
O-Desmethyltramadol exists within this complex pharmacological and social context, with its history shaped by its development, clinical utility, and the broader dynamics of opioid use and regulation.
Harm Reduction
Harm Reduction
Fentanyl Testing
Before using any powder or pressed pill sold as O-DSMT, always test with fentanyl immunoassay strips. The research chemical market has seen increasing adulteration with illicit fentanyl and its analogues. A single fentanyl-contaminated dose can be lethal even to individuals with significant opioid tolerance. Fentanyl test strips are widely available and can detect most — though not all — fentanyl analogues .
Start Low, Go Slow
O-DSMT is significantly more potent than tramadol. For opioid-naive individuals, an appropriate starting dose is 5-10 mg orally, with effects assessed over at least 90 minutes before considering redosing. Potency can vary substantially between batches in the unregulated market, making every new batch effectively an unknown dose. Never assume a new batch matches a previous one.
Volumetric Dosing
For powder-form O-DSMT, volumetric dosing is strongly recommended. Dissolve a known quantity in a measured volume of propylene glycol or distilled water to create a solution of known concentration (e.g., 10 mg/mL). Use an oral syringe for precise measurement. Attempting to weigh individual doses of a potent powder with consumer-grade scales introduces unacceptable error margins — a milligram-class scale with 1mg precision is the absolute minimum, and even these can be unreliable below 10-15 mg.
Never Combine with Depressants
The combination of O-DSMT with benzodiazepines, alcohol, GHB/GBL, barbiturates, gabapentinoids (pregabalin/gabapentin), or other opioids is the single most dangerous pattern of use. These combinations cause synergistic respiratory depression and are responsible for the majority of opioid-related deaths. Even seemingly mild depressants like sedating antihistamines or muscle relaxants increase risk.
Naloxone Accessibility
Unlike tramadol overdose — where seizures may complicate the clinical picture — O-DSMT overdose presents as a pure opioid emergency responsive to naloxone (Narcan). Anyone using O-DSMT should have naloxone readily available and ensure that someone nearby knows how to administer it. Naloxone is available without prescription in most US states and can be obtained from pharmacies and harm reduction organizations .
Tolerance and Dependence Awareness
Mu-opioid agonists produce tolerance rapidly. What was an effective dose on day one may be insufficient by day five, creating pressure to escalate. Avoid daily use to minimize tolerance development and physical dependence. If withdrawal symptoms emerge upon cessation, this indicates physical dependence has developed and abrupt discontinuation may cause significant discomfort.
Route of Administration
Oral administration is the safest route. Insufflation (snorting) increases the speed of onset and peak blood levels, raising overdose risk. Intravenous use dramatically increases risk of overdose, infection, and vascular damage. There is no established safety profile for non-oral routes.
References
NEXT Distro. Fentanyl test strip instructions and distribution. National Harm Reduction Coalition. SAMHSA. Naloxone. Substance Abuse and Mental Health Services Administration.
Toxicity & Safety
Toxicity Profile
O-Desmethyltramadol occupies a unique toxicological position: it is pharmacologically a pure mu-opioid agonist more potent than its parent tramadol, yet its G-protein biased signaling profile may confer a degree of respiratory safety not seen with conventional opioids.
Respiratory Depression
As a mu-opioid agonist, O-DSMT can cause dose-dependent respiratory depression, the hallmark danger of opioid toxicity. However, research suggests that the compound's ceiling on beta-arrestin2 recruitment — which plateaus at only 10-18% of maximum even at concentrations equivalent to gram-level doses — may limit lethal respiratory depression to a higher threshold than classical opioids . This does not mean O-DSMT is safe at high doses; it means fatal overdose from the opioid mechanism alone may require relatively larger doses than equipotent amounts of morphine or fentanyl.
Seizure Risk
Unlike tramadol, which carries a well-documented seizure risk attributable to its serotonergic (SNRI) activity, O-DSMT is not expected to lower the seizure threshold through the same mechanism, since it lacks significant serotonin reuptake inhibition . This represents a meaningful safety distinction: tramadol-associated seizures are a serotonergic phenomenon, not an opioid one. However, any substance that causes CNS depression can potentially contribute to seizure risk in susceptible individuals, particularly in polysubstance contexts.
Combination Dangers
The greatest acute toxicity risk with O-DSMT arises from polysubstance use. Combining O-DSMT with other CNS depressants — benzodiazepines, alcohol, gabapentinoids, other opioids, or sedating antihistamines — can produce synergistic respiratory depression that overcomes any ceiling effect the compound may possess on its own. Most opioid-related fatalities involve multiple substances .
Dependence and Withdrawal
As a mu-opioid agonist, O-DSMT carries significant potential for physical dependence and withdrawal with regular use. Tolerance develops to analgesic and euphoric effects, potentially driving dose escalation. Withdrawal symptoms mirror those of other opioids: dysphoria, anxiety, muscle aches, insomnia, gastrointestinal distress, lacrimation, and rhinorrhea. The timeline and severity are expected to be similar to tramadol withdrawal, though without the SNRI withdrawal component.
Limited Clinical Data
Because O-DSMT has primarily circulated as a research chemical rather than an approved medication, clinical toxicology data are limited. Most available information is extrapolated from tramadol pharmacology, pharmaceutical development data, and case reports. This uncertainty itself constitutes a risk factor .
References
Uprety R et al. Desmetramadol is identified as a G-protein biased mu opioid receptor agonist. Front Pharmacol. 2020;10:1680. Grond S, Sablotzki A. Clinical pharmacology of tramadol. Clin Pharmacokinet. 2004;43(13):879-923. Ramachandran S et al. Tramadol poisoning and its management and complications: a scoping review. BMC Emerg Med. 2023;23:89. PubChem. Desmetramadol. CID 9838803.
Addiction Potential
moderately addictive with a high potential for abuse
Overdose Information
Overdose Information
Recognition
O-DSMT overdose presents as a classic opioid overdose syndrome characterized by the triad of:
- Respiratory depression: Slow, shallow, or absent breathing (fewer than 12 breaths per minute, progressing to apnea)
- Miosis: Pinpoint pupils (though this may be absent in severe hypoxia or mixed overdose)
- Decreased consciousness: Ranging from drowsiness to complete unresponsiveness
Additional signs may include cyanosis (blue-tinged lips and fingertips), gurgling or snoring sounds indicating airway obstruction, cold and clammy skin, and a weak pulse. Because O-DSMT lacks tramadol's SNRI component, seizures are not a primary feature of pure O-DSMT overdose, unlike tramadol overdose where tonic-clonic seizures are well-documented.
Emergency Response
Call emergency services (911) immediately — do not wait to see if the person "sleeps it off." Opioid overdose is a progressive emergency that can escalate from respiratory depression to respiratory arrest and death within minutes.
Naloxone (Narcan)
Naloxone is effective against O-DSMT overdose. As a pure mu-opioid agonist, O-DSMT's effects are fully reversible by naloxone — this is a meaningful advantage over tramadol overdose, where seizures from the serotonergic component are not opioid-mediated and will not respond to naloxone .
Administer naloxone intranasally (4 mg spray in one nostril) or intramuscularly (0.4 mg injection). If no response occurs within 2-3 minutes, administer a second dose. Be aware that O-DSMT's duration of action may exceed that of naloxone, meaning re-sedation can occur as naloxone wears off — ongoing medical monitoring is essential.
Recovery Position
If the person is unconscious but breathing, place them in the recovery position (on their side with the upper leg bent forward) to prevent aspiration of vomit. Keep the airway clear. Monitor breathing continuously until emergency services arrive.
Post-Overdose
Any opioid overdose requiring naloxone reversal demands emergency department evaluation, even if the person appears to fully recover. Observation for re-sedation, assessment for aspiration pneumonia, and evaluation of organ function are medically necessary.
References
Boyer EW. Management of opioid analgesic overdose. N Engl J Med. 2012;367(2):146-155.
Dangerous Interactions
The combinations listed below may be life-threatening. Independent research should always be conducted to ensure safety when combining substances.
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Compounding CNS depression with anticholinergic effects; risk of cardiac events and respiratory failure
Severe respiratory depression risk; leading cause of polydrug overdose
Compounding CNS depression with anticholinergic effects; risk of cardiac events and respiratory failure
Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Compounding respiratory depression and overdose risk
Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths
Compounding CNS depression with anticholinergic effects; risk of cardiac events and respiratory failure
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Severe respiratory depression risk; leading cause of polydrug overdose
Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths
Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths
Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths
Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths
Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths
Severe respiratory depression risk; leading cause of polydrug overdose
Risk of serotonin syndrome and severe respiratory depression; potentially fatal
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Severe respiratory depression risk; leading cause of polydrug overdose
Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths
Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Compounding respiratory depression and overdose risk
Severe respiratory depression risk; leading cause of polydrug overdose
Severe respiratory depression risk; leading cause of polydrug overdose
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Risk of serotonin syndrome and severe respiratory depression; potentially fatal
Severe respiratory depression risk; leading cause of polydrug overdose
Severe respiratory depression risk; leading cause of polydrug overdose
Severe respiratory depression risk; leading cause of polydrug overdose
Tolerance
| Full | develops with prolonged and repeated use |
| Half | 3 - 7 days |
| Zero | 1 - 2 weeks |
Cross-tolerances
Legal Status
There is little information online regarding the international legalities of O-Desmethyltramadol possession but it is confirmed as a controlled substance within the United Kingdom.
Germany:** O-DSMT is not a controlled substance under the BtMG. It is legal, as long as it is not sold for human consumption, according to §2 AMG.
Sweden: O-DSMT is a controlled substance and considered a narcotic by law.
Switzerland:** O-DSMT is not controlled under Buchstabe A, B, C and D. It could be considered legal.
United Kingdom:** It is illegal to produce, supply, or import this drug under the Psychoactive Substance Act, which came into effect on May 26th, 2016.
Responsible use
Opioid
O-Desmethyltramadol (Wikipedia)
O-Desmethyltramadol (Isomer Design)
Experience Reports (1)
Tips (7)
Opioid tolerance and cross-tolerance are complex with O-Desmethyltramadol. Switching between different opioids requires careful dose conversion. Do not assume equivalent effects at standard conversion ratios; start lower than calculated.
Never combine O-Desmethyltramadol with benzodiazepines, alcohol, gabapentinoids, or other depressants. This dramatically increases respiratory depression risk. The majority of opioid overdose deaths involve a second depressant.
O-Desmethyltramadol (O-DSMT) is the primary active metabolite of tramadol and provides a cleaner opioid experience without tramadol's SNRI and seizure-risk properties. However, it still carries full opioid addiction and overdose potential.
In most US states, Good Samaritan laws protect you from drug charges if you call 911 for an overdose. Never hesitate to call emergency services. A legal charge is infinitely preferable to a death.
Signs of opioid overdose from O-Desmethyltramadol: slow or stopped breathing, blue lips or fingertips, pinpoint pupils, gurgling sounds, unresponsiveness. If you see these, administer naloxone immediately and call 911.
O-DSMT appears to have minimal serotonin activity compared to tramadol. However, do not assume it is completely safe to combine with serotonergic drugs. Exercise caution with DXM potentiation as both affect the opioid system.
Community Discussions (1)
See Also
References (4)
- Opioid receptors — Pasternak & Pan Annual Review of Pharmacology (2013)paper
- PubChem: O-Desmethyltramadol
PubChem compound page for O-Desmethyltramadol (CID: 9838803)
pubchem - O-Desmethyltramadol - TripSit Factsheet
TripSit factsheet for O-Desmethyltramadol
tripsit - O-Desmethyltramadol - Wikipedia
Wikipedia article on O-Desmethyltramadol
wikipedia